NASDAQ:RCKT Rocket Pharmaceuticals (RCKT) Stock Price, News & Analysis $2.11 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.10 -0.01 (-0.52%) As of 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Rocket Pharmaceuticals Stock (NASDAQ:RCKT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Rocket Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.03▼$2.2750-Day Range$2.11▼$3.5052-Week Range$2.03▼$5.45Volume2.56 million shsAverage Volume2.45 million shsMarket Capitalization$235.60 millionP/E RatioN/ADividend YieldN/APrice Target$7.77Consensus RatingModerate Buy Company Overview Rocket Pharmaceuticals, Inc. is a biotechnology company developing gene therapies for rare, serious diseases, with a focus on inherited disorders that often affect children. Its research programs use lentiviral and adeno-associated viral (AAV) vector technologies to deliver therapeutic genes to patients’ cells. The company’s pipeline has included programs targeting conditions such as Fanconi anemia, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, Danon disease and arrhythmogenic cardiomyopathy. Rocket conducts research and clinical development from its base in Cranbury, New Jersey, and works to advance its therapies through clinical testing and regulatory review.AI Generated. May Contain Errors. Read More Rocket Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreRCKT MarketRank™: 3.09569247546 of 5 starsRocket Pharmaceuticals scored higher than 62% of companies evaluated by MarketBeat, and ranked 653rd out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingRocket Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on 1 strong buy rating, 5 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialRocket Pharmaceuticals has a consensus price target of $7.77, representing about 278.2% upside from its current price of $2.06.Amount of Analyst CoverageRocket Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Rocket Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Rocket Pharmaceuticals are expected to decrease in the coming year, from ($1.38) to ($1.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rocket Pharmaceuticals is -13.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rocket Pharmaceuticals is -13.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRocket Pharmaceuticals has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.80% of the float of Rocket Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRocket Pharmaceuticals has a short interest ratio ("days to cover") of 9.07.Change versus previous monthShort interest in Rocket Pharmaceuticals has recently decreased by 0.24%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRocket Pharmaceuticals does not currently pay a dividend.Dividend GrowthRocket Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.7 / 5News Sentiment-0.23 News SentimentRocket Pharmaceuticals has a news sentiment score of -0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Rocket Pharmaceuticals this week, compared to 2 articles on an average week.MarketBeat Follows3 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Rocket Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $283,580.00 in company stock.Percentage Held by Insiders21.30% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.39% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rocket Pharmaceuticals' insider trading history. Receive RCKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RCKT Stock News HeadlinesRocket Pharmaceuticals (NASDAQ:RCKT) Earns Buy Rating from Chardan CapitalNovember 19 at 2:24 AM | americanbankingnews.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Rocket Pharmaceuticals (RCKT) and Revvity (RVTY)November 17 at 11:04 PM | theglobeandmail.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 19 at 1:00 AM | Profits Run (Ad)Rocket Pharmaceuticals (NASDAQ:RCKT) Stock: Insider Sarbani Chaudhuri Sells 4,872 SharesNovember 13, 2026 | insidertrades.comRocket Pharmaceuticals Inc (RCKT)October 9, 2026 | za.investing.comAnalysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), Rocket Pharmaceuticals (RCKT)October 9, 2026 | theglobeandmail.comRocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facilityOctober 7, 2026 | proactiveinvestors.comRocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor WebinarOctober 7, 2026 | businesswire.comSee More Headlines RCKT Stock Analysis - Frequently Asked Questions How have RCKT shares performed this year? Rocket Pharmaceuticals' stock was trading at $3.51 at the beginning of 2026. Since then, RCKT shares have decreased by 41.5% and is now trading at $2.0550. How were Rocket Pharmaceuticals' earnings last quarter? Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) issued its quarterly earnings results on Thursday, November, 12th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.40) by $0.03. When did Rocket Pharmaceuticals IPO? Rocket Pharmaceuticals (RCKT) raised $94 million in an initial public offering on Friday, February 6th 2015. The company issued 6,700,000 shares at $13.00-$15.00 per share. Who are Rocket Pharmaceuticals' major shareholders? Rocket Pharmaceuticals' top institutional shareholders include Marshall Wace LLP (3.20%), State Street Corp (1.71%), Goldman Sachs Group Inc. (1.67%) and Jump Financial LLC (0.38%). Insiders that own company stock include Gaurav Shah, Martin Wilson, Christopher James Stevens, Gotham Makker, Sarbani Chaudhuri, Jonathan David Schwartz, Aaron Ondrey, David P Southwell, David P Southwell, John Militello, Mark Andrew White, Elisabeth Bjork and Kinnari Patel. View institutional ownership trends. How do I buy shares of Rocket Pharmaceuticals? Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rocket Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rocket Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Pfizer (PFE), Micron Technology (MU), Alibaba Group (BABA), Tesla (TSLA) and Intel (INTC). Company Calendar Last Earnings11/12/2026Today11/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 RCKT's financial health is in the Yellow zone, according to TradeSmith. RCKT has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RCKT CIK1281895 Webwww.rocketpharma.com Phone(609) 659-8001Fax646-224-9585Employees202Year Founded2018Price Target and Rating Average Price Target for Rocket Pharmaceuticals$7.77 High Price Target$15.00 Low Price Target$2.95 Potential Upside/Downside+268.4%Consensus RatingModerate Buy Rating Score (0-4)2.55 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$223.12 million Net MarginsN/A Pretax MarginN/A Return on Equity-51.84% Return on Assets-43.04% Debt Debt-to-Equity Ratio0.15 Current Ratio7.26 Quick Ratio7.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.93 per share Price / Book0.72Miscellaneous Outstanding Shares111,660,000Free Float87,876,000Market Cap$235.60 million OptionableOptionable Beta0.51 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:RCKT) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rocket Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.